消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2021 CSCO临床指南：胃癌的诊断和治疗（英文版）

中国临床肿瘤学会 中国临床肿瘤学会

治疗胃癌诊断

本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。

中文标题：

2021 CSCO临床指南：胃癌的诊断和治疗（英文版）

英文标题：

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

发布机构：

中国临床肿瘤学会

发布日期：

简要介绍：

本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a97061c00212583c, title=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）, enTitle=The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021, guiderFrom=中国临床肿瘤学会, authorId=0, author=, summary=本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。, cover=https://img.medsci.cn/202175/1625470678288_5433779.jpeg, journalId=0, articlesId=null, associationId=863, associationName=中国临床肿瘤学会, associationIntro=null, copyright=0, guiderPublishedTime=null, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。</span></p>, tagList=[TagDto(tagId=65, tagName=治疗), TagDto(tagId=438, tagName=胃癌), TagDto(tagId=757, tagName=诊断)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=438, articleKeyword=胃癌, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=14836, appHits=942, showAppHits=0, pcHits=2198, showPcHits=13890, likes=4, shares=74, comments=40, approvalStatus=1, publishedTime=Mon Jul 05 15:40:21 CST 2021, publishedTimeString=null, pcVisible=1, appVisible=1, editorId=5433779, editor=Oranhyg是正经人, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=Oranhyg是正经人, createdTime=Mon Jul 05 15:38:09 CST 2021, updatedBy=5433779, updatedName=Oranhyg是正经人, updatedTime=Sat Jan 06 17:44:46 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf)])
2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf
下载请点击：
评论区 (26)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2022-03-15 吴卓远108

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2022-02-25 ms4000001880486183

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-11-04 ms2000000908561621

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-23 ms6000000590698351

    有中文吗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 147c0641m47暂无昵称

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2017 嗜酸性筋膜炎的诊断标准，严重性分级和治疗指南

国外皮肤性病相关专家小组（统称） · 2017-12-13

2017 ASA立场声明：成人失眠症的心理/行为治疗

澳大拉西亚睡眠协会(ASA,Australasian Sleep Association) · 2017-06-20

2017 NAMS立场声明：激素治疗

北美绝经学会(NAMS,The North American Menopause Society) · 2017-06-24

解读2015年美国风湿病学会强直性脊柱炎和放射学阴性中轴型脊柱关节炎新的治疗推荐

暂未更新 · 2016-07-30

中国成人艰难梭菌感染诊断和治疗专家共识

暂未更新 · 2017-06-20

2016年中国超重/肥胖医学营养治疗专家共识解读

暂未更新 · 2017-05-30

拓展阅读

总生存期近17个月！BMJ：这类胃癌患者治疗获益更大，死亡风险更低

研究表明抗PD-1抗体tislelizumab联合化疗治疗局部晚期不可切除或转移性胃或胃食管交界处腺癌，患者可获得更高的总生存期，且安全性可控。

读书报告 | 免疫化疗重塑免疫反应促进胃癌一线治疗应答

晚期胃食管腺癌（GEA）的一线治疗目前已向同步化学免疫治疗转变。抗PD-1治疗在胃食管腺癌中的疗效中规中矩且具有异质性。

读书报告 | 特瑞普利联合化疗围手术期治疗局部晚期胃癌和胃-食管结合部癌的II期临床研究

中山大学肿瘤防治中心王峰、徐瑞华教授团队发起的开放、随机对照、两中心II期临床研究，比较围手术期使用特瑞普利单抗联合化疗与单独化疗对cT3-4aN+M0胃或胃食管交界处腺癌患者的疗效。

J Clin Pathol：NTRK基因改变在肝样胃癌中的特异性富集

NTRK基因改变与dMMR状态之间的关系可能因肿瘤生物学特性的不同而有所差异，这对于未来的研究和临床实践具有重要的指导意义。

吕坤/张妍/孙仰白/马明哲团队《自然·通讯》：靶向 SOX13 可抑制呼吸链超级复合物的组装，克服胃癌的铁变态反应耐药性

研究进一步揭示了扎那米韦通过抑制SOX13/SCAF1轴增强细胞对铁死亡敏感性，逆转胃癌顺铂耐药的作用及机制，为扎那米韦的临床新应用提供一定的理论基础。

【衡道丨笔记】胃癌精准治疗的生物标志物探索

“复旦大学附属中山医院病理科32周年系列公开课”的课程中，王妍老师为大家带来了胃癌精准治疗的生物标志物探索的内容。摘要如下：